Perkins Capital Management Inc Lowers stake in Rockwell Medical Inc (RMTI)

Rockwell Medical Inc (RMTI) : Perkins Capital Management Inc reduced its stake in Rockwell Medical Inc by 1.75% during the most recent quarter end. The investment management company now holds a total of 478,550 shares of Rockwell Medical Inc which is valued at $4,263,881 after selling 8,500 shares in Rockwell Medical Inc , the firm said in a disclosure report filed with the SEC on Apr 18, 2016.Rockwell Medical Inc makes up approximately 5.08% of Perkins Capital Management Inc’s portfolio.

Rockwell Medical Inc opened for trading at $8.72 and hit $8.93 on the upside on Friday, eventually ending the session at $8.91, with a gain of 2.41% or 0.21 points. The heightened volatility saw the trading volume jump to 2,63,637 shares. Company has a market cap of $459 M.

Other Hedge Funds, Including , Sigma Planning Corp sold out all of its stake in RMTI during the most recent quarter. The investment firm sold 13,100 shares of RMTI which is valued $116,721. Simplex Trading added RMTI to its portfolio by purchasing 49,894 company shares during the most recent quarter which is valued at $443,059. Rockwell Medical Inc makes up approx 0.07% of Simplex Trading’s portfolio. Integrated Investment Consultants added RMTI to its portfolio by purchasing 3,000 company shares during the most recent quarter which is valued at $26,640. Rockwell Medical Inc makes up approx 0.02% of Integrated Investment Consultants’s portfolio.Creative Planning boosted its stake in RMTI in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 54,279 shares of Rockwell Medical Inc which is valued at $396,237.

On the company’s financial health, Rockwell Medical Inc reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Feb 29, 2016. Analyst had a consensus of $0.02. The company had revenue of $14.10 million for the quarter, compared to analysts expectations of $19.97 million. The company’s revenue was down -2.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.14 EPS.

Many Wall Street Analysts have commented on Rockwell Medical Inc. Rockwell Medical Inc was Downgraded by Stifel to ” Hold” on Mar 1, 2016.

Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.

Leave a Reply

Rockwell Medical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Rockwell Medical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.